Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)

SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details) $ in Thousands	1 Months Ended								3 Months Ended				6 Months Ended		12 Months Ended	18 Months Ended
	Apr. 30, 2021 USD ($)	Feb. 28, 2021 USD ($)	Jan. 31, 2021 USD ($)	Feb. 29, 2020 USD ($)	Dec. 31, 2019	Oct. 31, 2019 USD ($) agreement	Jan. 31, 2019 USD ($)	Oct. 31, 2018 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2020	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaborations
Upfront payment received													$ 125,000
Accretion expense									$ 0		$ 1,000		700	$ 1,100
Payment of cost share to collaboration partner													8,346
Accounts receivable									17,198				17,198			$ 17,198	$ 15,472
License agreement with unrelated third party
Collaborations
Revenue recognized														4,000
Proceeds from License Fees Received		$ 4,000
One-time fee received from license rights granted		$ 4,000
Specified Development Events [Member]
Collaborations
Contingent payments													279,500
Specified Regulatory Events [Member]
Collaborations
Contingent payments													283,100
Specified Product Launch Events [Member]
Collaborations
Contingent payments													796,000
Development and regulatory milestones by non-CNS disease products
Collaborations
Contingent payments													330,000
Development and regulatory milestones by non-CNS disease products \| Milestone payments on a product-by-product basis
Collaborations
Contingent payments													100,000
Development and regulatory milestones by CNS disease products
Collaborations
Contingent payments													255,000
Development and regulatory milestones by CNS disease products \| Milestone payments on a product-by-product basis
Collaborations
Contingent payments													150,000
Maximum
Collaborations
Contingent payments													1,300,000
Grifols
Collaborations
Contingent payments													277,500
Upfront payment received							$ 30,000
Revenue, remaining performance obligation																	5,000
Deferred revenue									200				200			200	700
Revenue, cumulative catch-up										$ 25,000
Grifols \| Commercial milestones
Collaborations
Contingent payments							$ 297,500
Grifols \| Upon EMA approval of fostamatinib for treatment of chronic ITP
Collaborations
Revenue, cumulative catch-up										$ 20,000
Kissei
Collaborations
Contingent payments								$ 147,000
Upfront payment received								$ 33,000
Revenue, remaining performance obligation									33,000				33,000			33,000
Knight \| Commercial and license agreements
Collaborations
Upfront payment received									2,000
Knight \| Maximum \| Commercial milestones \| Commercial and license agreements
Collaborations
Contingent payments									20,000
fostamatinib
Collaborations
Revenue recognized									0		5,500		0	8,500		10,500
Government contract			$ 16,500
Remaining amount of government award expected to be received in succeeding periods													6,000
fostamatinib \| Grifols
Collaborations
Revenue recognized									1,200		0		1,200	1,000
Collaborative payment received				$ 20,000
Markup percentage					30.00%
fostamatinib \| Grifols \| Upon EMA approval of fostamatinib for treatment of chronic ITP
Collaborations
Contingent payments				17,500
fostamatinib \| Grifols \| Creditable advance royalty payment
Collaborations
Collaborative payment received				$ 2,500
fostamatinib \| Grifols \| Maximum
Collaborations
Royalty payment as a percentage of net sales															30.00%
fostamatinib \| Kissei
Collaborations
Revenue recognized									2,500		0		2,600	0
Deferred revenue									1,400				1,400			1,400	1,400
Collaborative payment received	$ 5,000
fostamatinib \| Medison Pharma \| Financing arrangement
Collaborations
Upfront payment received						$ 5,000
Financing liability with accreted interest expense									5,700				5,700			5,700	5,600
Accretion expense									0		300		0	300
Deferred revenue									100				$ 100			100
fostamatinib \| Medison Pharma \| Commercial and license agreements
Collaborations
Upfront payment received						$ 5,000
Number of agreements \| agreement						2
R552
Collaborations
Company's percentage of development costs													20.00%
Financing component liability									57,900				$ 57,900			57,900
Financing liability interest accretion discount rate													6.40%
Financing liability with accreted interest expense									53,000				$ 53,000			53,000	$ 60,700
Development costs due to collaboration partner									8,300				8,300			8,300
Revenue, remaining performance obligation									67,100				67,100			67,100
R552 \| Maximum
Collaborations
Funding commitment									65,000				65,000			$ 65,000
Non-CNS penetrant IP
Collaborations
Revenue recognized												$ 60,400
CNS penetrant IP
Collaborations
Revenue recognized									300		3,300		500	3,500
CNS penetrant IP \| Licensed Rights
Collaborations
Revenue, remaining performance obligation											6,700			6,700
Research and development services \| Grifols
Collaborations
Revenue recognized									$ 200		$ 400		$ 500	$ 400